TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05581927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Whole-Body Hypothermia
Description: patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard Whole-Body Hypothermia
Description: patients were allocated to standard Whole-Body Hypothermia
Study: NCT05260190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: 30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tSMS
Description: 30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
Study: NCT04878510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
Study: NCT05660356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pfizer provided placebo
Study: NCT04878510

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo will be given as continuous infusion.
Study: NCT05010863

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample
Study: NCT05922943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony & Health program
Description: Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
Study: NCT05665478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose prediction using population pharmacokinetic models
Description: Dose prediction using population pharmacokinetic models.
Study: NCT05036655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative glycemic management pathway
Description: The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
Study: NCT05010863

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample

Intervention type: OTHER
Intervention: Blood collection
Description: The subject will be drawn a 5ml blood sample
Study: NCT05411224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom made orthosis
Description: In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
Study: NCT06281314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vespa software
Description: The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vespa software
Description: The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vespa software
Description: The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
Study: NCT06353204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Halt-intervention
Description: The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
Study: NCT06402526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Epilepsy Education Package
Description: MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care consisting of epilepsy education
Description: This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
Study: NCT06310642

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Immediate descent from altitude.
Description: Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate descent from altitude.
Description: Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
Study: NCT05551039

Intervention type: OTHER
Intervention: Retrospective patient chart review
Description: Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
Study: NCT06441994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSW-1025
Description: PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
Study: NCT06310642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg
Description: Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
Study: NCT05979701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
Study: NCT05086406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of Video and Virtual Pre-operative Counseling
Description: Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
Study: NCT05965583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT06291012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quick response: Amoxicillin for 3 days
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed response: Amoxicillin for 5 days
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quick response: Amoxicillin for 5 days
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed response: Amoxicillin for 7 days
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days
Study: NCT06556875

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT
Description: high intensity interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT combined IET
Description: high intensity interval training combined with isometric exercise training
Study: NCT05040971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Description: Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
Study: NCT05934591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Wise
Description: The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Wise
Description: The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Wise
Description: The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Study: NCT06321445

Intervention type: OTHER
Intervention: providing ASA score
Description: ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.

Intervention type: OTHER
Intervention: providing ASA score
Description: ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
Study: NCT05430503

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise
Description: DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise
Description: DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
Study: NCT05441605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections
Description: Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.

Intervention type: OTHER
Group type: OTHER
Intervention: Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections
Description: Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections
Description: Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections
Description: Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
Study: NCT06353295

Intervention type: OTHER
Group type: OTHER
Intervention: P4P intervention
Description: The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
Study: NCT05412745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaloidon Plus
Description: topical application; twice daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: silicone gel
Description: topical application; twice daily
Study: NCT05934890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Walvax PCV13-TT
Description: PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer PCV13
Description: PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
Study: NCT06007885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathways and Resources to Engagement and Participation (PREP)
Description: Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
Study: NCT05503615

Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: No application will be made to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM Technique Application
Description: Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
Study: NCT05169047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subthreshold Spinal Cord Stimulation
Description: SCS will be programmed at subthreshold stimulation.
Study: NCT05961085

Intervention type: PROCEDURE
Intervention: Adductor Canal Catheter
Description: Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
Study: NCT05798832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtually reality training group
Description: BLS Training with VR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training group
Description: BLS Training with Traditional
Study: NCT05453656

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise
Description: physical activity promotion and engagement following kidney transplantation